New HIV plaque titration; application to the assay of neutralizing antibody.
A simple, sensitive and accurate plaque assay was developed using HPB-Ma, a variant of the human T-cell line HPB-ALL, which becomes adherent to the substratum after infection with an amphotropic murine sarcoma virus (MSVa). The simplicity of this novel plaque assay allowed us to examine a large number of serum samples from patients with HIV infection for neutralizing antibody activity against two human immunodeficiency virus type-1 (HIV-1) strains. During the progression of clinical disease, the neutralizing activity in the sera from two individual patients remained unchanged or increased. A patient with a known time of HIV infection produced cross-neutralizing antibody at 25-34 weeks. The neutralizing activity in the sera from 17 asymptomatic carriers, four patients with AIDS-related complex and four AIDS patients was also examined and was found to be unrelated to the clinical stage.
Tsunetsugu-Yokota
Y
Y
Department of Immunology, National Institute of Health, Tokyo, Japan.
Ohshima
M
M
Naito
A
A
Chermann
J C
JC
Shih
J
J
Yoshikura
H
H
D002460:Cell Line; D005069:Evaluation Studies as Topic; D015483:HIV Antibodies / Q000032:analysis* / Q000097:blood; D015658:HIV Infections / Q000209:etiology / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006367:HeLa Cells; D006801:Humans; D009500:Neutralization Tests / Q000379:methods / Q000706:statistics & numerical data; D012680:Sensitivity and Specificity; D013997:Time Factors; D010948:Viral Plaque Assay / Q000379:methods* / Q000706:statistics & numerical data; D014773:Virology / Q000379:methods* / Q000706:statistics & numerical data
D015483:HIV Antibodies